Cue BiopharmaCUE -0.87%59 Operating Margin % is -94.32% as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.11 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Cue Biopharma ranks better than 53.76% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Cue Biopharma's Operating Income for the
three
months ended in Mar. 2026 was $-5.36 Mil. Cue Biopharma's Revenue for the
three
months ended in Mar. 2026 was $5.69 Mil. Therefore, Cue Biopharma's Operating Margin % for the quarter that ended in Mar. 2026 was -94.32%.
Good Sign:
Cue Biopharma Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Cue Biopharma's Operating Margin % or its related term are showing as below:
CUE'
s Operating Margin % Range Over the Past 10 Years
Min: -4297.35 Med: -1005.17 Max: -59.83
Current: -59.83
CUE's Operating Margin % is ranked better than 53.76% of 945
companies
in the Biotechnology industry
Industry Median: -86.89
vs CUE: -59.83
Cue Biopharma's 5-Year Average Operating Margin % Growth Rate was 32.40% per year.
Cue Biopharma's Operating Income for the
three
months ended in Mar. 2026 was $-5.36 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-19.58 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Cue Biopharma Operating Margin % Related Terms
Cue Biopharma Operating Margin % Historical Data
* Premium members only.
The historical data trend for Cue Biopharma's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUE vs TELO, ACET, AARD: Operating Margin % Comparison
For the Biotechnology subindustry, Cue Biopharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Cue Biopharma's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a Operating Margin % of -94.32% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #437 out of 945 companies in the Biotechnology industry, placing it in the top 46.2%.
Is Cue Biopharma's Operating Margin % too high?
Cue Biopharma's current Operating Margin % is -94.32%. Based on the distribution chart, Cue Biopharma ranks #437 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Operating Margin % compare to TELO and ACET?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #437 out of 945 companies for Operating Margin %. This puts Cue Biopharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Operating Margin % is -94.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.11, compared to a current price of $25.79 — trading 58.5% below its estimated fair value. The current Operating Margin % is -94.32%. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Operating Margin % is -94.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (CUE) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of $25.79 is trading 58.5% below its estimated GF Value™ of $62.11.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for CUE:
Operating Margin %: -94.32%
GF Value™: $62.11 vs. price of $25.79 (58.5% below fair value)
No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score
Get the complete analysis for CUE
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
